GSK Investigational Site

Grove City, Pennsylvania 16127

0 studies enrolling now · 5 studies all time

What they study most

Acellular Pertussis, Diphtheria, Herpes Simplex Infection, Infections, Papillomavirus, Influenza, Tetanus

Studies at this site

• Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 — Completed
• HerpeVac Trial for Young Women — Completed
• Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years — Completed
• Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America — Completed
• Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older — Completed